Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Judge

Showing results (51-60 of 260) with videos related to

Pageof 26
Sort By:
Journal of Cardiovascular Translational Research|May 1, 2015
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac AmyloidosisMarc K Halushka, George Eng, A Bernard Collins, et al.
Spine|February 1, 2005
Toward an understanding of dural ectasia: a light microscopy study in a murine model of Marfan syndromeKevin B Jones, Loretha Myers, Daniel P Judge, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 21, 2007
Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantationJonathan D Cuda, William M Baldwin, Charles Steenbergen, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 1, 2017
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 yearsFabio A Barroso, Daniel P Judge, Ben Ebede, et al.
Plos One|September 18, 2012
Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndromeRussell A Gould, Ravi Sinha, Hamza Aziz, et al.
Implementation Science Communications|October 11, 2023
Use of a multi-phased approach to identify and address facilitators and barriers to the implementation of a population-wide genomic screening programCaitlin G Allen, Katherine Sterba, Samantha Norman, et al.
ESC Heart Failure|August 25, 2021
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACTJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Cardiology and Therapy|December 19, 2025
Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid CardiomyopathyDaniel P Judge, Margarita Udall, Andrew M Rosen, et al.
Nature Clinical Practice. Cardiovascular Medicine|November 3, 2005
Reversible cardiomyopathy caused by administration of interferon alphaAarif Y Khakoo, Marc K Halushka, J Eduardo Rame, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 22, 2026
Acoramidis for the management of transthyretin amyloid cardiomyopathy: Clinical evidence and implications for pharmacist-led careJoseph S Van Tuyl, Katherine E Di Palo, Trina Huynh, et al.
Pageof 26

Showing results (51-60 of 260) with videos related to

Sort By:
Pageof 26
Journal of Cardiovascular Translational Research|May 1, 2015
Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac AmyloidosisMarc K Halushka, George Eng, A Bernard Collins, et al.
Spine|February 1, 2005
Toward an understanding of dural ectasia: a light microscopy study in a murine model of Marfan syndromeKevin B Jones, Loretha Myers, Daniel P Judge, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 21, 2007
Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantationJonathan D Cuda, William M Baldwin, Charles Steenbergen, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 1, 2017
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 yearsFabio A Barroso, Daniel P Judge, Ben Ebede, et al.
Plos One|September 18, 2012
Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndromeRussell A Gould, Ravi Sinha, Hamza Aziz, et al.
Implementation Science Communications|October 11, 2023
Use of a multi-phased approach to identify and address facilitators and barriers to the implementation of a population-wide genomic screening programCaitlin G Allen, Katherine Sterba, Samantha Norman, et al.
ESC Heart Failure|August 25, 2021
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACTJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Cardiology and Therapy|December 19, 2025
Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid CardiomyopathyDaniel P Judge, Margarita Udall, Andrew M Rosen, et al.
Nature Clinical Practice. Cardiovascular Medicine|November 3, 2005
Reversible cardiomyopathy caused by administration of interferon alphaAarif Y Khakoo, Marc K Halushka, J Eduardo Rame, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 22, 2026
Acoramidis for the management of transthyretin amyloid cardiomyopathy: Clinical evidence and implications for pharmacist-led careJoseph S Van Tuyl, Katherine E Di Palo, Trina Huynh, et al.
Pageof 26